Lost but making progress - Where will new analgesic drugs come from?

Science Translational Medicine

Volumn 6, Issue 249, 2014, Pages

  Borsook, David ^a   Hargreaves, Richard ^a   Bountra, Chas ^b   Porreca, Frank ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BIOLOGICAL MARKER;

ANALGESIA; BRAIN DISEASE; CHRONIC PAIN; CLINICAL RESEARCH; DRUG DEVELOPMENT; DRUG SCREENING; EXPERIMENTAL MODEL; GENETICS; HUMAN; NERVE CELL PLASTICITY; NOCICEPTION; NONHUMAN; PAIN; PHARMACODYNAMICS; PHENOTYPE; REVIEW; SENSITIZATION; PRECLINICAL STUDY; RESEARCH;

ANALGESICS; CHRONIC PAIN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; PAIN; RESEARCH;

EID: 84907411229     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008320     Document Type: Review

References (199)

1. I. Melnikova, Pain market. Nat. Rev. Drug Discov. 9, 589-590 (2010).
2. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research (Institute of Medicine, Washington, DC, 2011).
3. W. F. Stewart, J. A. Ricci, E. Chee, D. Morganstein, R. Lipton, Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290, 2443-2454 (2003).
4. J. Serra, H. Bostock, R. Solà, J. Aleu, E. García, B. Cokic, X. Navarro, C. Quiles, Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats. Pain 153, 42-55 (2012).
5. J. Van Hees, J. Gybels, C nociceptor activity in human nerve during painful and non painful skin stimulation. J. Neurol. Neurosurg. Psychiatry 44, 600-607 (1981).
6. Y. Indo, Nerve growth factor and the physiology of pain: Lessons from congenital insensitivity to pain with anhidrosis. Clin. Genet. 82, 341-350 (2012).
7. Y. Indo, M. Tsuruta, Y. Hayashida, M. A. Karim, K. Ohta, T. Kawano, H. Mitsubuchi, H. Tonoki, Y. Awaya, I. Matsuda, Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat. Genet. 13, 485-488 (1996).
8. S. D. Dib-Hajj, S. G. Waxman, Translational pain research: Lessons from genetics and genomics. Sci. Transl. Med. 6, 249sr4 (2014).
9. R. M. Plenge, J. D. Greenberg, L. M. Mangravite, J. M. Derry, E. A. Stahl, M. J. Coenen, A. Barton, L. Padyukov, L. Klareskog, P. K. Gregersen, X. Mariette, L.W. Moreland, S. L. Bridges Jr., N. de Vries, T. W. Huizinga, H. J. Guchelaar; International Rheumatoid Arthritis Consortium (INTERACT); S. H. Friend, G. Stolovitzky, Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Nat. Genet. 45, 468-469 (2013).
10. C. F. Barrett, A. M. van den Maagdenberg, R. R. Frants, M. D. Ferrari, Familial hemiplegic migraine. Adv. Genet. 63, 57-83 (2008).
11. T. Freilinger, V. Anttila, B. de Vries, R. Malik, M. Kallela, G. M. Terwindt, P. Pozo-Rosich, B. Winsvold, D. R. Nyholt, W. P. van Oosterhout, V. Artto, U. Todt, E. Hämäläinen, J. Fernández-Morales, M. A. Louter, M. A. Kaunisto, J. Schoenen, O. Raitakari, T. Lehtimäki, M. Vila-Pueyo, H. Göbel, E. Wichmann, C. Sintas, A. G. Uitterlinden, A. Hofman, F. Rivadeneira, A. Heinze, E. Tronvik, C. M. van Duijn, J. Kaprio, B. Cormand, M. Wessman, R. R. Frants, T. Meitinger, B. Müller-Myhsok, J. A. Zwart, M. Färkkilä, A. Macaya, M. D. Ferrari, C. Kubisch, A. Palotie, M. Dichgans, A. M. van den Maagdenberg; International Headache Genetics Consortium, Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat. Genet. 44, 777-782 (2012).
12. v1.7 sodium channel: From molecule to man. Nat. Rev. Neurosci. 14, 49-62 (2013).
13. v1.8 mutations in painful neuropathy. Proc. Natl. Acad. Sci. U.S.A. 109, 19444-19449 (2012).
14. v1.7 sodium channel. Ann. N. Y. Acad. Sci. 1184, 196-207 (2010).
15. A. H. Rowe, Y. Xiao, M. P. Rowe, T. R. Cummins, H. H. Zakon, Voltage-gated sodium channel in grasshopper mice defends against bark scorpion toxin. Science 342, 441-446 (2013).
16. T. Pexton, T. Moeller-Bertram, J. M. Schilling, M. S. Wallace, Targeting voltage-gated calcium channels for the treatment of neuropathic pain: A review of drug development. Expert Opin. Investig. Drugs 20, 1277-1284 (2011).
17. T. S. Han, R. W. Teichert, B. M. Olivera, G. Bulaj, Conus venoms - A rich source of peptide-based therapeutics. Curr. Pharm. Des. 14, 2462-2479 (2008).
18. A. M. Mayer, K. B. Glaser, C. Cuevas, R. S. Jacobs, W. Kem, R. D. Little, J. M. McIntosh, D. J. Newman, B. C. Potts, D. E. Shuster, The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci. 31, 255-265 (2010).
19. R. W. Teichert, B. M. Olivera, Natural products and ion channel pharmacology. Future Med. Chem. 2, 731-744 (2010).
20. P. J. Dyck, S. Peroutka, C. Rask, E. Burton, M. K. Baker, K. A. Lehman, D. A. Gillen, J. L. Hokanson, P. C. O'Brien, Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 48, 501-505 (1997).
21. R. Rukwied, A. Mayer, O. Kluschina, O. Obreja, M. Schley, M. Schmelz, NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin. Pain 148, 407-413 (2010).
22. S. C. Apfel, Nerve growth factor for the treatment of diabetic neuropathy: What went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol. 50, 393-413 (2002).
23. X. Chevalier, F. Eymard, P. Richette, Biologic agents in osteoarthritis: Hopes and disappointments. Nat. Rev. Rheumatol. 9, 400-410 (2013).
24. K. Garber, Fate of novel painkiller mAbs hangs in balance. Nat. Biotechnol. 29, 173-174 (2011).
25. N. Katz, D. G. Borenstein, C. Birbara, C. Bramson, M. A. Nemeth, M. D. Smith, M. T. Brown, Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 152, 2248-2258 (2011).
26. M. T. Brown, F. T. Murphy, D. M. Radin, I. Davignon, M. D. Smith, C. R. West, Tanezumab reduces osteoarthritic knee pain: Results of a randomized, double-blind, placebo-controlled phase III trial. J. Pain 13, 790-798 (2012).
27. T. A. Norbury, A. J. MacGregor, J. Urwin, T. D. Spector, S. B. McMahon, Heritability of responses to painful stimuli in women: A classical twin study. Brain 130, 3041-3049 (2007).
28. U. Anand, P. Facer, Y. Yiangou, M. Sinisi, M. Fox, T. McCarthy, C. Bountra, Y. E. Korchev, P. Anand, Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur. J. Pain 17, 1012-1026 (2013).
29. 2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Med. 14, 1557-1568 (2013).
30. E. Marion, O. R. Song, T. Christophe, J. Babonneau, D. Fenistein, J. Eyer, F. Letournel, D. Henrion, N. Clere, V. Paille, N. C. Guérineau, J. P. Saint André, P. Gersbach, K. H. Altmann, T. P. Stinear, Y. Comoglio, G. Sandoz, L. Preisser, Y. Delneste, E. Yeramian, L. Marsollier, P. Brodin, Mycobacterial toxin induces analgesia in Buruli ulcer by targeting the angiotensin pathways. Cell 157, 1565-1576 (2014).
31. A. S. Rice, R. H. Dworkin, T. D. McCarthy, P. Anand, C. Bountra, P. I. McCloud, J. Hill, G. Cutter, G. Kitson, N. Desem, M. Raff; EMA401-003 study group, EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 383, 1637-1647 (2014).
32. P. P. Humphrey, The discovery and development of the triptans, a major therapeutic breakthrough. Headache 48, 685 -687 (2008).
33. P. Tfelt-Hansen, A. Hougaard, Sumatriptan: A review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. Expert Opin. Drug Metab. Toxicol. 9, 91-103 (2013).
34. A. Negro, L. Lionetto, M. Simmaco, P. Martelletti, CGRP receptor antagonists: An expanding drug class for acute migraine? Expert Opin. Investig. Drugs 21, 807-818 (2012).
35. H. C. Diener, P. Barbanti, C. Dahlöf, U. Reuter, J. Habeck, J. Podhorna, BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia 31, 573-584 (2011).
36. D. J. Hewitt, S. K. Aurora, D. W. Dodick, P. J. Goadsby, Y. J. Ge, R. Bachman, D. Taraborelli, X. Fan, C. Assaid, C. Lines, T. W. Ho, Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31, 712-722 (2011).
37. Y. C. Lee, P. P.Chen, A reviewof SSRIs and SNRIs in neuropathic pain. Expert Opin. Pharmacother. 11, 2813-2825 (2010).
38. C. P. Watson, I. Gilron, J. Sawynok, M. E. Lynch, Nontricyclic antidepressant analgesics and pain: Are serotonin norepinephrine reuptake inhibitors (SNRIs) any better? Pain 152, 2206-2210 (2011).
39. R. B. Raffa, H. Buschmann, T. Christoph, G. Eichenbaum, W. Englberger, C. M. Flores, T. Hertrampf, B. Kögel, K. Schiene, W. Straßburger, R. Terlinden, T. M. Tzschentke, Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin. Pharmacother. 13, 1437-1449 (2012).
40. R. Riemsma, C. Forbes, J. Harker, G. Worthy, K. Misso, M. Schäfer, J. Kleijnen, S. Stürzebecher, Systematic review of tapentadol in chronic severe pain. Curr. Med. Res. Opin. 27, 1907-1930 (2011).
41. C. K. Jones, S. C. Peters, H. E. Shannon, Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J. Pharmacol. Exp. Ther. 312, 726-732 (2005).
42. D. Yarnitsky, M.Granot, H. Nahman-Averbuch, M. Khamaisi, Y. Granovsky, Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153, 1193-1198 (2012).
43. R. M. Botting, Inhibitors of cyclooxygenases: Mechanisms, selectivity and uses. J. Physiol. Pharmacol. 57 (Suppl. 5), 113-124 (2006).
44. A. V. Apkarian, M. N. Baliki, M. A. Farmer, Predicting transition to chronic pain. Curr. Opin. Neurol. 26, 360- 367 (2013).
45. D. Borsook, L. Becerra, W. A. Carlezon Jr., M. Shaw, P. Renshaw, I. Elman, J. Levine, Reward-aversion circuitry in analgesia and pain: Implications for psychiatric disorders. Eur. J. Pain 11, 7-20 (2007).
46. F. Denk, S. B. McMahon, I. Tracey, Pain vulnerability: A neurobiological perspective. Nat. Neurosci. 17, 192-200 (2014).
47. D. A. Dunn, D. Apanovitch, M. Follettie, T. He, T. Ryan, Taking a systems approach to the identification of novel therapeutic targets and biomarkers. Curr. Pharm. Biotechnol. 11, 721-734 (2010). Downloaded from stm.sciencemag.org on September 21, 2014
48. J. A. Lowe, P. Jones, D. M. Wilson, Network biology as a new approach to drug discovery. Curr. Opin. Drug Discov. Devel. 13, 524 -526 (2010).
49. E. E. Schadt, S. H. Friend, D. A. Shaywitz, A network view of disease and compound screening. Nat. Rev. Drug Discov. 8, 286-295 (2009).
50. T.Mori, Y. Shibasaki, K. Matsumoto, M. Shibasaki, M. Hasegawa, E. Wang, D. Masukawa, K. Yoshizawa, S. Horie, T. Suzuki, Mechanisms that underlie m-opioid receptor agonist- induced constipation: Differential involvement of μ-opioid receptor sites and responsible regions. J. Pharmacol. Exp. Ther. 347, 91-99 (2013).
51. N. B. Finnerup, Add-on therapy: When two are not better than one. Pain 154, 2579-2580 (2013).
52. S. Tesfaye, S. Wilhelm, A. Lledo, A. Schacht, T. Tölle, D. Bouhassira, G. Cruccu, V. Skljarevski, R. Freynhagen, Duloxetine and pregabalin: High-dose monotherapy or their combination? The "COMBO-DN study" - A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 154, 2616-2625 (2013).
53. R. Morphy, Z. Rankovic, Fragments, network biology and designing multiple ligands. Drug Discov. Today 12, 156-160 (2007).
54. R. Morphy, Z. Rankovic, Designing multiple ligands - Medicinal chemistry strategies and challenges. Curr. Pharm. Des. 15, 587-600 (2009).
55. S. M. Stahl, Multifunctional drugs: A novel concept for psychopharmacology. CNS Spectr. 14, 71-73 (2009).
56. A. Minarini, A. Milelli, E. Simoni, M. Rosini, M. L. Bolognesi, C. Marchetti, V. Tumiatti, Multifunctional tacrine derivatives in Alzheimer's disease. Curr. Top. Med. Chem. 13, 1771-1786 (2013).
57. I. Gilron, J. M. Bailey, D. Tu, R. R. Holden, D. F. Weaver, R. L. Houlden, Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352, 1324-1334 (2005).
58. I. Gilron, J. M. Bailey, D. Tu, R. R. Holden, A. C. Jackson, R. L. Houlden, Nortriptyline and gabapentin, alone and in combination for neuropathic pain: A double-blind, randomised controlled crossover trial. Lancet 374, 1252-1261 (2009).
59. L. E. Chaparro, P. J. Wiffen, R. A. Moore, I. Gilron, Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst. Rev. 7, CD008943 (2012).
60. D. Borsook, A. D. Edwards, Antineuropathic effects of the antibiotic derivative spicamycin KRN5500. Pain Med. 5, 104-108 (2004).
61. L. A. Kobierski, S. Abdi, L. DiLorenzo, N. Feroz, D. Borsook, A single intravenous injection of KRN5500 (antibiotic spicamycin) produces long-term decreases in multiple sensory hypersensitivities in neuropathic pain. Anesth. Analg. 97, 174-182 (2003).
62. J. S. Mogil, Animal models of pain: Progress and challenges. Nat. Rev. Neurosci. 10, 283-294 (2009).
63. A. S. Rice, D. Cimino-Brown, J. C. Eisenach, V. K. Kontinen, M. L. Lacroix-Fralish, I. Machin; Preclinical Pain Consortium, J. S. Mogil, T. Stöhr, Animal models and the prediction of efficacy in clinical trials of analgesic drugs: A critical appraisal and call for uniform reporting standards. Pain 139, 243-247 (2008).
64. A. Taneja, V. L. Di Iorio, M. Danhof, O. Della Pasqua, Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov. Today 17, 837-849 (2012).
65. D. Wilkes, G. Li, C. F. Angeles, J. T. Patterson, L. Y. Huang, A large animal neuropathic pain model in sheep: A strategy for improving the predictability of preclinical models for therapeutic development. J. Pain Res. 5, 415-424 (2012).
66. D. Borsook, J. Upadhyay, M. Klimas, A. J. Schwarz, A. Coimbra, R. Baumgartner, E. George, W. Z. Potter, T. Large, D. Bleakman, J. Evelhoch, S. Iyengar, L. Becerra, R. J. Hargreaves, Decision-making using fMRI in clinical drug development: Revisiting NK-1 receptor antagonists for pain. Drug Discov. Today 17, 964-973 (2012).
67. M. K. Herbert, P. Holzer, Why are substance P(NK1)-receptor antagonists ineffective in pain treatment? Anaesthesist 51, 308-319 (2002).
68. R. Hill, NK1 (substance P) receptor antagonists - Why are they not analgesic in humans? Trends Pharmacol. Sci. 21, 244-246 (2000).
69. T. Bisogno, M. Maccarrone, Latest advances in the discovery of fatty acid amide hydrolase inhibitors. Expert Opin. Drug Discov. 8, 509-522 (2013).
70. P. Pacher, G. Kunos, Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J. 280, 1918-1943 (2013).
71. J. S. Mogil, "What is the reason for lack of translation in the pain field?" Pain Research Forum, 28 March 2011; http://www.painresearchforum.org/forums/discussion/4561-what-reason-lack-translation-pain-field [accessed 24 June 2014].
72. G. T. Whiteside, J. D. Pomonis, J. D. Kennedy, An industry perspective on the role and utility of animal models of pain in drug discovery. Neurosci. Lett. 557, 65-72 (2013).
73. v1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 86, 629-640 (2001).
74. S. G. Waxman, Nav1.7, its mutations, and the syndromes that they cause. Neurology 69, 505-507 (2007).
75. B-inflamed and normal skin. Br. J. Clin. Pharmacol. 75, 404-414 (2013).
76. M. P. Maher, A. Bhattacharya, H. Ao, N. Swanson, N. T. Wu, J. Freedman, M. Kansagara, B. Scott, D. H. Li, W. A. Eckert III, Y. Liu, K. Sepassi, M. Rizzolio, A. Fitzgerald, J. Liu, B. J. Branstetter, J. C. Rech, A. D. Lebsack, J. G. Breitenbucher, A. D.Wickenden, S. R. Chaplan, Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist. Eur. J. Pharmacol. 663, 40-50 (2011).
77. U. Bingel, J. Lorenz, E. Schoell, C. Weiller, C. Büchel, Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 120, 8-15 (2006).
78. F. Eippert, U. Bingel, E. D. Schoell, J. Yacubian, R. Klinger, J. Lorenz, C. Büchel, Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63, 533-543 (2009).
79. N. Stein, C. Sprenger, J. Scholz, K. Wiech, U. Bingel, White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain 153, 2210-2217 (2012).
80. A. D. Craig, Interoception: The sense of the physiological condition of the body. Curr. Opin. Neurobiol. 13, 500-505 (2003).
81. H. L. Fields, A. I. Basbaum, M. M. Heinricher, in Textbook of Pain (Churchill Livingstone, Edinburgh, 2005), vol. 5, pp. 125-142.
82. B. Heppelmann, K. Messlinger, H. G. Schaible, R. F. Schmidt, Nociception and pain. Curr. Opin. Neurobiol. 1, 192-197 (1991).
83. H. L. Fields, Understanding how opioids contribute to reward and analgesia. Reg. Anesth. Pain Med. 32, 242-246 (2007).
84. M. C. Lee, I. Tracey, Unravelling the mystery of pain, suffering, and relief with brain imaging. Curr. Pain Headache Rep. 14, 124-131 (2010).
85. N. Danziger, Neurological basis of the emotional dimension of pain. Rev. Neurol. 162, 395-399 (2006).
86. H. L. Fields, Pain: An unpleasant topic. Pain (Suppl. 6), S61-S69 (1999).
87. O. G. Berge, Predictive validity of behavioural animal models for chronic pain. Br. J. Pharmacol. 164, 1195-1206 (2011).
88. C. J. Vierck, P. T. Hansson, R. P. Yezierski, Clinical and pre-clinical pain assessment: Are we measuring the same thing? Pain 135, 7-10 (2008).
89. H. Kehlet, T. S. Jensen, C. J. Woolf, Persistent postsurgical pain: Risk factors and prevention. Lancet 367, 1618-1625 (2006).
90. M. Costigan, I. Belfer, R. S. Griffin, F. Dai, L. B. Barrett, G. Coppola, T. Wu, C. Kiselycznyk, M. Poddar, Y. Lu, L. Diatchenko, S. Smith, E. J. Cobos, D. Zaykin, A. Allchorne, E. Gershon, J. Livneh, P. H. Shen, L. Nikolajsen, J. Karppinen, M. Männikkö, A. Kelempisioti, D. Goldman, W. Maixner, D. H. Geschwind, M. B. Max, Z. Seltzer, C. J. Woolf, Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain 133, 2519-2527 (2010).
91. I. Tegeder, M. Costigan, R. S. Griffin, A. Abele, I. Belfer, H. Schmidt, C. Ehnert, J. Nejim, C. Marian, J. Scholz, T. Wu, A. Allchorne, L. Diatchenko, A. M. Binshtok, D. Goldman, J. Adolph, S. Sama, S. J. Atlas, W. A. Carlezon, A. Parsegian, J. Lötsch, R. B. Fillingim, W. Maixner, G. Geisslinger, M. B. Max, C. J. Woolf, GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat. Med. 12, 1269-1277 (2006).
92. M. De Felice, R. Sanoja, R. Wang, L. Vera-Portocarrero, J. Oyarzo, T. King, M. H. Ossipov, T. W. Vanderah, J. Lai, G. O. Dussor, H. L. Fields, T. J. Price, F. Porreca, Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain. Pain 152, 2701-2709 (2011).
93. C. A. Dominguez, L. Li, O. Lidman, T. Olsson, Z. Wiesenfeld-Hallin, F. Piehl, X. J. Xu, Both MHC and non-MHC genes regulate development of experimental neuropathic pain in rats. Neurosci. Lett. 442, 284-286 (2008).
94. C. A. Dominguez, O. Lidman, J. X. Hao, M. Diez, J. Tuncel, T. Olsson, Z. Wiesenfeld-Hallin, F. Piehl, X. J. Xu, Genetic analysis of neuropathic pain-like behavior following peripheral nerve injury suggests a role of the major histocompatibility complex in development of allodynia. Pain 136, 313-319 (2008).
95. R. R. Ji, Z. Z. Xu, G. Strichartz, C. N. Serhan, Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci. 34, 599-609 (2011).
96. C. Ndong, R. P. Landry, J. A. DeLeo, E. A. Romero-Sandoval, Mitogen activated protein kinase phosphatase-1 prevents the development of tactile sensitivity in a rodent model of neuropathic pain. Mol. Pain 8, 34 (2012).
97. H. G. Thyregod, M. C. Rowbotham, M. Peters, J. Possehn, M. Berro, K. L. Petersen, Natural history of pain following herpes zoster. Pain 128, 148-156 (2007).
98. D. Yarnitsky, M. Granot, Y. Granovsky, Pain modulation profile and pain therapy: Between pro- and antinociception. Pain 155, 663-665 (2014).
99. C. N. Serhan, N. A. Petasis, Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922-5943 (2011).
100. G. J. Bennett, What is spontaneous pain and who has it? J. Pain 13, 921-929 (2012).
101. A. Tappe-Theodor, R. Kuner, Studying ongoing and spontaneous pain in rodents - Challenges and opportunities. Eur. J. Neurosci. 39, 1881-1890 (2014).
102. S. S. Negus, T. W. Vanderah, M. R. Brandt, E. J. Bilsky, L. Becerra, D. Borsook, Preclinical assessment of candidate analgesic drugs: Recent advances and future challenges. J. Pharmacol. Exp. Ther. 319, 507-514 (2006).
103. C. J. Woolf, Overcoming obstacles to developing new analgesics. Nat. Med. 16, 1241-1247 (2010).
104. J. M. Boyce-Rustay, C. Zhong, R. Kohnken, S. J. Baker, G. H. Simler, E. J. Wensink, M. W. Decker, P. Honore, Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. Neuropharmacology 58, 537-543 (2010).
105. T. King, L. Vera-Portocarrero, T. Gutierrez, T. W. Vanderah, G. Dussor, J. Lai, H. L. Fields, F. Porreca, Unmasking the tonic-aversive state in neuropathic pain. Nat. Neurosci. 12, 1364-1366 (2009).
106. E. D. Legg, A. Novejarque, A. S. Rice, The Three Ages of Rat: The influence of rodent age on affective and cognitive outcome measures in peripheral neuropathic pain. Pain 144, 12-13 (2009).
107. C. Qu, T. King, A. Okun, J. Lai, H. L. Fields, F. Porreca, Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy. Pain 152, 1641-1648 (2011).
108. V. C. Wallace, A. R. Segerdahl, J. Blackbeard, T. Pheby, A. S. Rice, Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. Neurosci. Lett. 448, 153-156 (2008).
109. J. P. Johansen, H. L. Fields, B. H. Manning, The affective component of pain in rodents: Direct evidence for a contribution of the anterior cingulate cortex. Proc. Natl. Acad. Sci. U.S.A. 98, 8077-8082 (2001).
110. K. J. Sufka, R. A. Hughes, T. M. McCormick, J. L. Borland, Opiate effects on isolation stress in domestic fowl. Pharmacol. Biochem. Behav. 49, 1011-1015 (1994).
111. F. C. Colpaert, J. P. Tarayre,M. Alliaga, L. A. Bruins Slot, N. Attal,W. Koek, Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats. Pain 91, 33-45 (2001).
112. T. J. Martin, S. A. Kim, N. L. Buechler, F. Porreca, J. C. Eisenach, Opioid self-administration in the nerve-injured rat: Relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology 106, 312-322 (2007).
113. S. G. Sotocinal, R. E. Sorge, A. Zaloum, A. H. Tuttle, L. J. Martin, J. S. Wieskopf, J. C. Mapplebeck, P. Wei, S. Zhan, S. Zhang, J. J. McDougall, O. D. King, J. S. Mogil, The Rat Grimace Scale: A partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol. Pain 7, 55 (2011).
114. E. J. Cobos, N. Ghasemlou, D. Araldi, D. Segal, K. Duong, C. J. Woolf, Inflammation-induced decrease in voluntary wheel running in mice: A nonreflexive test for evaluating inflammatory pain and analgesia. Pain 153, 876-884 (2012).
115. G. W. Stevenson, H. Mercer, J. Cormier, C. Dunbar, L. Benoit, C. Adams, J. Jezierski, A. Luginbuhl, E. J. Bilsky, Monosodium iodoacetate-induced osteoarthritis produces pain-depressed wheel running in rats: Implications for preclinical behavioral assessment of chronic pain. Pharmacol. Biochem. Behav. 98, 35-42 (2011).
116. N. Andrews, S. Harper, Y. Issop, A. S. Rice, Novel, nonreflex tests detect analgesic action in rodents at clinically relevant concentrations. Ann. N. Y. Acad. Sci. 1245, 11-13 (2011).
117. P. Jirkof, N. Cesarovic, A. Rettich, F. Nicholls, B. Seifert, M. Arras, Burrowing behavior as an indicator of post-laparotomy pain in mice. Front. Behav. Neurosci. 4, 165 (2010).
118. G. S. Borszcz, Increases in vocalization and motor reflex thresholds are influenced by the site of morphine microinjection: Comparisons following administration into the periaqueductal gray, ventral medulla, and spinal subarachnoid space. Behav. Neurosci. 109, 502-522 (1995).
119. M. Kurejova, U. Nattenmüller, U. Hildebrandt, D. Selvaraj, S. Stösser, R. Kuner, An improved behavioural assay demonstrates that ultrasound vocalizations constitute a reliable indicator of chronic cancer pain and neuropathic pain. Mol. Pain 6, 18 (2010).
120. L. Becerra, D. Borsook, Signal valence in the nucleus accumbens to pain onset and offset. Eur. J. Pain 12, 866-869 (2008).
121. P. Schweinhardt, D. A. Seminowicz, E. Jaeger, G. H. Duncan, M. C. Bushnell, The anatomy of the mesolimbic reward system: A link between personality and the placebo analgesic response. J. Neurosci. 29, 4882-4887 (2009).
122. S. Leknes, M. Lee, C. Berna, J. Andersson, I. Tracey, Relief as a reward: Hedonic and neural responses to safety from pain. PLOS One 6, e17870 (2011).
123. M. N. Baliki, A. Mansour, A. T. Baria, L. Huang, S. E. Berger, H. L. Fields, A. V. Apkarian, Parceling human accumbens into putative core and shell dissociates encoding of values for reward and pain. J. Neurosci. 33, 16383-16393 (2013).
124. A. R. Segerdahl, J. Xie, K. Paterson, J. D. Ramirez, I. Tracey, D. L. Bennett, Imaging the neural correlates of neuropathic pain and pleasurable relief associated with inherited erythromelalgia in a single subject with quantitative arterial spin labelling. Pain 153, 1122-1127 (2012).
125. E. Navratilova, J. Y. Xie, A. Okun, C. Qu, N. Eyde, S. Ci, M. H. Ossipov, T. King, H. L. Fields, F. Porreca, Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry. Proc. Natl. Acad. Sci. U.S.A. 109, 20709-20713 (2012).
126. L. Becerra, H. C. Breiter, R. Wise, R. G. Gonzalez, D. Borsook, Reward circuitry activation by noxious thermal stimuli. Neuron 32, 927 -946 (2001).
127. M. Pais-Vieira, P. Aguiar, D. Lima, V. Galhardo, Inflammatory pain disrupts the orbitofrontal neuronal activity and risk-assessment performance in a rodent decision-making task. Pain 153, 1625-1635 (2012).
128. T. Esch, G. B. Stefano, The neurobiology of pleasure, reward processes, addiction and their health implications. Neuro. Endocrinol. Lett. 25, 235-251 (2004).
129. R. J. Hargreaves, The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 83, 349-353 (2008).
130. J. Upadhyay, J. Anderson, A. J. Schwarz, A. Coimbra, R. Baumgartner, G. Pendse, E. George, L. Nutile, D. Wallin, J. Bishop, S. Neni, G. Maier, S. Iyengar, J. L. Evelhoch, D. Bleakman, R. Hargreaves, L. Becerra, D. Borsook, Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology 36, 2659-2673 (2011).
131. D. Borsook, L. Becerra, R. Hargreaves, A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 5, 411-424 (2006).
132. L. Becerra, G. Pendse, P. C. Chang, J. Bishop, D. Borsook, Robust reproducible resting state networks in the awake rodent brain. PLOS One 6, e25701 (2011).
133. D. Borsook, G. Pendse, M. Aiello-Lammens, M. Glicksman, J. Gostic, S. Sherman, J. Korn, M. Shaw, K. Stewart, R. Gostic, S. Bazes, R. Hargreaves, L. Becerra, CNS response to a thermal stressor in human volunteers and rats may predict the clinical utility of analgesics. Drug Dev. Res. 68, 23-41 (2007).
134. L. Becerra, J. Upadhyay, P. C. Chang, J. Bishop, J. Anderson, R. Baumgartner, A. J. Schwarz, A. Coimbra, D. Wallin, L. Nutile, E. George, G. Maier, S. Sunkaraneni, S. Iyengar, J. L. Evelhoch, D. Bleakman, R. Hargreaves, D. Borsook, Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects. J. Pharmacol. Exp. Ther. 345, 41-51 (2013).
135. D. A. Seminowicz, A. L. Laferriere, M. Millecamps, J. S. Yu, T. J. Coderre, M. C. Bushnell, MRI structural brain changes associated with sensory and emotional function in a rat model of long-term neuropathic pain. Neuroimage 47, 1007-1014 (2009).
136. S. M. Gustin, C. C. Peck, S. L. Wilcox, P. G. Nash, G. M. Murray, L. A. Henderson, Different pain, different brain: Thalamic anatomy in neuropathic and non-neuropathic chronic pain syndromes. J. Neurosci. 31, 5956-5964 (2011).
137. M. Obermann, R. Rodriguez-Raecke, S. Naegel, D. Holle, D. Mueller, M. S. Yoon, N. Theysohn, S. Blex, H. C. Diener, Z. Katsarava, Gray matter volume reduction reflects chronic pain in trigeminal neuralgia. Neuroimage 74, 352-358 (2013).
138. C. R. Chapman, K. L. Casey, R. Dubner, K. M. Foley, R. H. Gracely, A. E. Reading, Pain measurement: An overview. Pain 22, 1-31 (1985).
139. G. A. Hawker, S. Mian, T. Kendzerska, M. French, Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 63 (Suppl. 11), S240 -S252 (2011).
140. A. V. Apkarian, M. N. Baliki, P. Y. Geha, Towards a theory of chronic pain. Prog. Neurobiol. 87, 81-97 (2009).
141. P. M. Grace, D. Hurley, D. T. Barratt, A. Tsykin, L. R. Watkins, P. E. Rolan, M. R. Hutchinson, Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: A novel correlational study design and bioinformatics approach in a graded chronic constriction injury model. J. Neurochem. 122, 976-994 (2012).
142. G. D. Slade,M. S. Conrad, L. Diatchenko, N. U. Rashid, S. Zhong, S. Smith, J. Rhodes, A.Medvedev, S. Makarov, W. Maixner, A. G. Nackley, Cytokine biomarkers and chronic pain: Association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness. Pain 152, 2802-2812 (2011).
143. I. A. Orlova, G. M. Alexander, R. A. Qureshi, A. Sacan, A. Graziano, J. E. Barrett, R. J. Schwartzman, S. K. Ajit, MicroRNA modulation in complex regional pain syndrome. J. Transl. Med. 9, 195 (2011).
144. D. Borsook, L. Becerra, R. Hargreaves, Biomarkers for chronic pain and analgesia. Part 1: The need, reality, challenges, and solutions. Discov. Med. 11, 197 -207 (2011).
145. D. Borsook, L. Becerra, R. Hargreaves, Biomarkers for chronic pain and analgesia. Part 2: How, where, and what to look for using functional imaging. Discov. Med. 11, 209-219 (2011).
146. M. M. Backonja, C. L. Coe, D. A. Muller, K. Schell, Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J. Neuroimmunol. 195, 157-163 (2008).
147. G. Lauria, G. Devigili, Skin biopsy as a diagnostic tool in peripheral neuropathy. Nat. Clin. Pract. Neurol. 3, 546 -557 (2007).
148. N. Üc¸eyler, D. Zeller, A. K. Kahn, S. Kewenig, S. Kittel-Schneider, A. Schmid, J. Casanova-Molla, K. Reiners, C. Sommer, Small fibre pathology in patients with fibromyalgia syndrome. Brain 136, 1857-1867 (2013).
149. D. A. Seminowicz, T. H. Wideman, L. Naso, Z. Hatami-Khoroushahi, S. Fallatah, M. A. Ware, P. Jarzem, M. C. Bushnell, Y. Shir, J. A. Ouellet, L. S. Stone, Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. J. Neurosci. 31, 7540-7550 (2011).
150. M. N. Baliki, B. Petre, S. Torbey, K.M. Herrmann, L. Huang, T. J. Schnitzer, H. L. Fields, A. V. Apkarian, Corticostriatal functional connectivity predicts transition to chronic back pain. Nat. Neurosci. 15, 1117-1119 (2012).
151. D. J. Pavlin, M. J. Sullivan, P. R. Freund, K. Roesen, Catastrophizing: A risk factor for post-surgical pain. Clin. J. Pain 21, 83-90 (2005).
152. M. U. Werner, J. M. Bischoff, Persistent postsurgical pain: Evidence from breast cancer surgery, groin hernia repair, and lung cancer surgery. Curr. Top. Behav. Neurosci. 10.1007/7854-2014-285 (2014).
153. D. Borsook, L. Becerra, CNS animal fMRI in pain and analgesia. Neurosci. Biobehav. Rev. 35, 1125-1143 (2011).
154. L. Becerra, J. Upadhyay, P. C. Chang, J. Bishop, J. Anderson, R. Baumgartner, A. J. Schwarz, A. Coimbra, D. Wallin, L. Nutile, E. George, G. Maier, S. Sunkaraneni, S. Iyengar, J. L. Evelhoch, D. Bleakman, R. Hargreaves, D. Borsook, Parallel buprenorphine phMRI responses in conscious rodents and healthy human subjects. J. Pharmacol. Exp. Ther. 345, 41-51 (2013).
155. D. Borsook, R. Hargreaves, L. Becerra, Can functional magnetic resonance imaging improve success rates in CNS drug discovery? Expert Opin. Drug Discov. 6, 597-617 (2011).
156. T. D. Wager, L. Y. Atlas, M. A. Lindquist, M. Roy, C. W. Woo, E. Kross, An fMRI-based neurologic signature of physical pain. N. Engl. J. Med. 368, 1388-1397 (2013).
157. A. Dickenson, H. Kehlet, Can we stop pain before it starts? Pain 155, 208-209 (2013).
158. F. Cauda, F. D'Agata, K. Sacco, S. Duca, D. Cocito, I. Paolasso, G. Isoardo, G. Geminiani, Altered resting state attentional networks in diabetic neuropathic pain. J. Neurol. Neurosurg. Psychiatry 81, 806-811 (2010).
159. A. J. Carinci, P. Mehta, P. J. Christo, Chronic pain in torture victims. Curr. Pain Headache Rep. 14, 73-79 (2010).
160. T. Moeller-Bertram, J. Keltner, I. A. Strigo, Pain and post traumatic stress disorder - Review of clinical and experimental evidence. Neuropharmacology 62, 586-597 (2012).
161. J. J. Marbach, D. M. Richlin, J. A. Lipton, Illness behavior, depression and anhedonia in myofascial face and back pain patients. Psychother. Psychosom. 39, 47-54 (1983).
162. I. Elman, J. K. Zubieta, D. Borsook, The missing p in psychiatric training: Why it is important to teach pain to psychiatrists. Arch. Gen. Psychiatry 68, 12-20 (2011).
163. U. Blankstein, J. Chen, N. E. Diamant, K. D. Davis, Altered brain structure in irritable bowel syndrome: Potential contributions of pre-existing and disease-driven factors. Gastroenterology 138, 1783-1789 (2010).
164. A. May, Chronic pain may change the structure of the brain. Pain 137, 7-15 (2008).
165. M. N. Baliki, T. J. Schnitzer, W. R. Bauer, A. V. Apkarian, Brain morphological signatures for chronic pain. PLOS One 6, e26010 (2011).
166. N. Maleki, C. Linnman, J. Brawn, R. Burstein, L. Becerra, D. Borsook, Her versus his migraine: Multiple sex differences in brain function and structure. Brain 135, 2546-2559 (2012).
167. L. A. Low, M. Millecamps, D. A. Seminowicz, L. Naso, S. J. Thompson, L. S. Stone, M. C. Bushnell, Nerve injury causes long-term attentional deficits in rats. Neurosci. Lett. 529, 103-107 (2012).
168. R. Rodriguez-Raecke, A. Niemeier, K. Ihle, W. Ruether, A. May, Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. J. Neurosci. 29, 13746-13750 (2009).
169. J. Lötsch, Genetic variability of pain perception and treatment - Clinical pharmacological implications. Eur. J. Clin. Pharmacol. 67, 541-551 (2011).
170. D. J. Hewitt, T. W. Ho, B. Galer, M. Backonja, P. Markovitz, A. Gammaitoni, D. Michelson, J. Bolognese, A. Alon, E. Rosenberg, G. Herman, H. Wang, Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 152, 514-521 (2011).
171. Learning from failure. Nat. Rev. Drug Discov. 9, 499 (2010).
172. R. Hromas, J. L. Abkowitz, A. Keating, Facing the NIH funding crisis: How professional societies can help. JAMA 308, 2343-2344 (2012).
173. K. Boadi, "Erosion of funding for the National Institutes of Health threatens U.S. leadership inbiomedical research," Center for American Progress, 25 March 2014; http://americanprogress. org/issues/economy/report/2014/03/25/86369/erosion-of-funding-for-the-national-institutes-of-health-threatens-u-s-leadership-in-biomedical-research/ [accessed 24 June 2014].
174. B. M. Silber, Driving drug discovery: The fundamental role of academic labs. Sci. Transl. Med. 2, 30cm16 (2010).
175. A. Schuhmacher, P. G. Germann, H. Trill, O. Gassmann, Models for open innovation in the pharmaceutical industry. Drug Discov. Today 18, 1133-1137 (2013).
176. New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts (Government Printing Office, Washington, DC, 2006).
177. T. Vos, A. D. Flaxman, M. Naghavi, R. Lozano, C. Michaud, M. Ezzati, K. Shibuya, J. A. Salomon, S. Abdalla, V. Aboyans, J. Abraham, I. Ackerman, R. Aggarwal, S. Y. Ahn, M. K. Ali, M. Alvarado, H. R. Anderson, L. M. Anderson, K. G. Andrews, C. Atkinson, L. M. Baddour, A. N. Bahalim, S. Barker-Collo, L. H. Barrero, D. H. Bartels, M. G. Basáñez, A. Baxter, M. L. Bell, E. J. Benjamin, D. Bennett, E. Bernabé, K. Bhalla, B. Bhandari, B. Bikbov, A. Bin Abdulhak, G. Birbeck, J. A. Black, H. Blencowe, J. D. Blore, F. Blyth, I. Bolliger, A. Bonaventure, S. Boufous, R. Bourne, M. Boussinesq, T. Braithwaite, C. Brayne, L. Bridgett, S. Brooker, P. Brooks, T. S. Brugha, C. Bryan-Hancock, C. Bucello, R. Buchbinder, G. Buckle, C. M. Budke, M. Burch, P. Burney, R. Burstein, B. Calabria, B. Campbell, C. E. Canter, H. Carabin, J. Carapetis, L. Carmona, C. Cella, F. Charlson, H. Chen, A. T. Cheng, D. Chou, S. S. Chugh, L. E. Coffeng, S. D. Colan, S. Colquhoun, K. E. Colson, J. Condon, M. D. Connor, L. T. Cooper, M. Corriere, M. Cortinovis, K. C. de Vaccaro, W. Couser, B. C. Cowie,M. H. Criqui, M. Cross, K. C. Dabhadkar,M. Dahiya, N. Dahodwala, J. Damsere-Derry, G. Danaei, A. Davis, D. De Leo, L. Degenhardt, R. Dellavalle, A. Delossantos, J. Denenberg, S. Derrett, D. C. Des Jarlais, S. D. Dharmaratne,M.Dherani, C. Diaz-Torne, H. Dolk, E. R.Dorsey, T. Driscoll, H. Duber, B. Ebel, K. Edmond, A. Elbaz, S. E. Ali, H. Erskine, P. J. Erwin, P. Espindola, S. E. Ewoigbokhan, F. Farzadfar, V. Feigin, D. T. Felson, A. Ferrari, C. P. Ferri, E. M. Fèvre, M. M. Finucane, S. Flaxman, L. Flood, K. Foreman, M. H. Forouzanfar, F.G. Fowkes, R. Franklin, M. Fransen, M. K. Freeman, B. J. Gabbe, S. E. Gabriel, E. Gakidou, H. A. Ganatra, B. Garcia, F. Gaspari, R. F. Gillum, G. Gmel, R. Gosselin, R. Grainger, J. Groeger, F. Guillemin, D. Gunnell, R. Gupta, J. Haagsma, H. Hagan, Y. A. Halasa, W. Hall, D. Haring, J. M. Haro, J. E. Harrison, R. Havmoeller, R. J. Hay, H. Higashi, C. Hill, B. Hoen, H. Hoffman, P. J. Hotez, D. Hoy, J. J. Huang, S. E. Ibeanusi, K. H. Jacobsen, S. L. James, D. Jarvis, R. Jasrasaria, S. Jayaraman, N. Johns, J. B. Jonas, G. Karthikeyan, N. Kassebaum, N. Kawakami, A. Keren, J. P. Khoo, C. H. King, L. M. Knowlton, O. Kobusingye, A. Koranteng, R. Krishnamurthi, R. Lalloo, L. L. Laslett, T. Lathlean, J. L. Leasher, Y. Y. Lee, J. Leigh, S. S. Lim, E. Limb, J. K. Lin, M. Lipnick, S. E. Lipshultz, W. Liu, M. Loane, S. L. Ohno, R. Lyons, J. Ma, J. Mabweijano, M. F. MacIntyre, R. Malekzadeh, L. Mallinger, S. Manivannan, W. Marcenes, L. March, D. J. Margolis, G. B. Marks, R. Marks, A. Matsumori, R. Matzopoulos, B. M. Mayosi, J. H. McAnulty, M. M. McDermott, N. McGill, J. McGrath, M. E. Medina-Mora, M. Meltzer, G. A. Mensah, T. R. Merriman, A. C. Meyer, V. Miglioli, M. Miller, T. R. Miller, P. B. Mitchell, A. O. Mocumbi, T. E. Moffitt, A. A. Mokdad, L. Monasta, M. Montico, M. Moradi-Lakeh, A. Moran, L. Morawska, R. Mori, M. E. Murdoch, M. K. Mwaniki, K. Naidoo, M. N. Nair, L. Naldi, K. M. Narayan, P. K. Nelson, R. G. Nelson, M. C. Nevitt, C. R. Newton, S. Nolte, P. Norman, R. Norman, M. O'Donnell, S. O'Hanlon, C. Olives, S. B. Omer, K. Ortblad, R. Osborne, D. Ozgediz, A. Page, B. Pahari, J. D. Pandian, A. P. Rivero, S. B. Patten, N. Pearce, R. P. Padilla, F. Perez-Ruiz, N. Perico, K. Pesudovs, D. Phillips, M. R. Phillips, K. Pierce, S. Pion, G. V. Polanczyk, S. Polinder, C. A. Pope III, S. Popova, E. Porrini, F. Pourmalek, M. Prince, R. L. Pullan, K. D. Ramaiah, D. Ranganathan, H. Razavi, M. Regan, J. T. Rehm, D. B. Rein, G. Remuzzi, K. Richardson, F. P. Rivara, T. Roberts, C. Robinson, F. R. De Leòn, L. Ronfani, R. Room, L. C. Rosenfeld, L. Rushton, R. L. Sacco, S. Saha, U. Sampson, L. Sanchez-Riera, E. Sanman, D. C. Schwebel, J. G. Scott, M. Segui-Gomez, S. Shahraz, D. S. Shepard, H. Shin, R. Shivakoti, D. Singh, G. M. Singh, J. A. Singh, J. Singleton, D. A. Sleet, K. Sliwa, E. Smith, J. L. Smith, N. J. Stapelberg, A. Steer, T. Steiner, W. A. Stolk, L. J. Stovner, C. Sudfeld, S. Syed, G. Tamburlini, M. Tavakkoli, H. R. Taylor, J. A. Taylor, W. J. Taylor, B. Thomas, W. M. Thomson, G. D. Thurston, I. M. Tleyjeh, M. Tonelli, J. A. Towbin, T. Truelsen, M. K. Tsilimbaris, C. Ubeda, E. A. Undurraga, M. J. van der Werf, J. van Os, M. S. Vavilala, N. Venketasubramanian, M. Wang, W. Wang, K. Watt, D. J. Weatherall, M. A. Weinstock, R. Weintraub, M. G. Weisskopf, M. M. Weissman, R. A. White, H. Whiteford, S. T. Wiersma, J. D. Wilkinson, H. C. Williams, S. R.Williams, E. Witt, F.Wolfe, A. D. Woolf, S. Wulf, P. H. Yeh, A. K. Zaidi, Z. J. Zheng, D. Zonies, A. D. Lopez, C. J. Murray, M. A. AlMazroa, Z. A. Memish, Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2163-2196 (2012).
178. O. Berton, E. J. Nestler, New approaches to antidepressant drug discovery: Beyond monoamines. Nat. Rev. Neurosci. 7, 137 -151 (2006).
179. B. Gomez-Mancilla, E. Marrer, J. Kehren, A. Kinnunen, G. Imbert, R. Hillebrand, M. Bergström, M. E. Schmidt, Central nervous system drug development: An integrative biomarker approach toward individualized medicine. NeuroRx 2, 683-695 (2005).
180. J. A. Gray, B. L. Roth, The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 12, 904-922 (2007).
181. N. M. Rupniak, Animal models of depression: Challenges from a drug development perspective. Behav. Pharmacol. 14, 385-390 (2003).
182. A. Talevi, C. L. Bellera, M. Di Ianni, M. Gantner, L. E. Bruno-Blanch, E. A. Castro, CNS drug development - Lost in translation? Mini Rev. Med. Chem. 12, 959-970 (2012).
183. J. Woodcock, J. Witter, R. A. Dionne, Stimulating the development of mechanism-based, individualized pain therapies. Nat. Rev. Drug Discov. 6, 703-710 (2007).
184. K. I. Kaitin, C. P. Milne, A dearth of new meds. Sci. Am. 305, 16 (2011).
185. F. Collins, An audience with...Francis Collins. Interviewed by Asher Mullard. Nat. Rev. Drug Discov. 10, 14 (2011).
186. Center for Drug Evaluation and Research, Analgesic Indications: Developing Drug and Biological Products (Food and Drug Administration, Silver Spring, MD, 2014).
187. W. Z. Potter, New era for novel CNS drug development. Neuropsychopharmacology 37, 278-280 (2012).
188. B. G. Oertel, J. Lötsch, Clinical pharmacology of analgesics assessed with human experimental pain models: Bridging basic and clinical research. Br. J. Pharmacol. 168, 534 - 553 (2013).
189. A. J. Schwarz, L. Becerra, J. Upadhyay, J. Anderson, R. Baumgartner, A. Coimbra, J. Evelhoch, R. Hargreaves, B. Robertson, S. Iyengar, J. Tauscher, D. Bleakman, D. Borsook, A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: Processes and requirements. Drug Discov. Today 16, 583-593 (2011).
190. A. J. Schwarz, L. Becerra, J. Upadhyay, J. Anderson, R. Baumgartner, A. Coimbra, J. Evelhoch, R. Hargreaves, B. Robertson, S. Iyengar, J. Tauscher, D. Bleakman, D. Borsook, A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: Protocol optimization and best practices. Drug Discov. Today 16, 671-682 (2011).
191. R. Wellenreuther, D. Keppler, D. Mumberg, K. Ziegelbauer, M. Lessl, Promoting drug discovery by collaborative innovation: A novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. Drug Discov. Today 17, 1242-1248 (2012).
192. The Harvard Clinical and Translational Science Center, Harvard Catalyst; http://catalyst.harvard.edu [accessed 24 June 2014].
193. Johns Hopkins School of Medicine, Brain Science Institute; http://www.brainscienceinstitute.org [accessed 24 June 2014].
194. SGC, Structural Genomics Consortium; http://www.thesgc.org [accessed 24 June 2014].
195. Kings College London, The London Pain Consortium; http://www.lpc.ac.uk [accessed 24 June 2014].
196. University of Munich, German Research Network on Neuropathic Pain; http://www.neuro.med.tu-muenchen.de/dfns/e [accessed 24 June 2014].
197. IMI, The Innovative Medicines Initiative; http://www.imi.europa.eu [accessed 24 June 2014].
198. NIH, NIH Common Fund; http://commonfund.nih.gov/publicprivate [accessed 24 June 2014].
199. NIH, NIH Accelerating Medicines Partnership; http://www.nih.gov/amp [accessed 24 June 2014].